CA-RECVUE
14.1.2021 15:02:34 CET | Business Wire | Press release
RecVue, provider of Order Lifecycle Management (OLM) solutions designed to modernize the complex order-to-cash (O2C) processes for enterprises, has raised $13 million in a Series A round. Cota Capital led the round, in which Epic Ventures and Long Light Capital also participated. RecVue will use the funding to expand its engineering, go-to-market efforts and international presence.
“We offer the industry’s only suite of OLM solutions that are purpose-built to address the growing gap between front- and back-office business processes,” said Nishant Nair, founder and CEO of RecVue. “This fundraising round provides a dynamic foundation for rapid growth in our go-to-market operations as well as allowing us to quickly add new capabilities to our OLM suite of applications to scale to the $150 billion revenue under management target.”
Bobby Yazdani, managing partner for Cota Capital, added “Since its launch, RecVue’s technology has been transforming the order-to-cash process, helping customers innovate and operate new business models and manage complex revenue streams at unprecedented scale, speed and efficiency. The RecVue leadership team has crafted a powerful strategic plan that has them poised to transform order-to-cash needs of hundreds of large enterprises and process billions of transactions over the next several years.”
The “middle office” is the command center for the enterprise, encompassing all the business functions that sit between the traditional front-and-back systems -- from initial engagement to managing relationships and complex order-to-cash processes such as billing, revenue management and channel partner compensation. The middle office presents a largely untapped opportunity to harness revenue potential by leveraging back-office data to influence front-office business decisions.
Yet, many organizations today are experiencing a growing “middle office” gap between their customer-facing front-office CRM systems and transaction-heavy, back-office ERP systems. Faced with data silos, fragmented and often manual processes, and custom-built applications and spreadsheets, many companies are forced to do complicated data integrations to make CRM and ERP systems work together.
RecVue addresses the middle office gap more efficiently and effectively by fully automating the complex order-to-cash processes for billing, revenue, accruals management and channel partner payments. Additionally, RecVue provides robust analytics and reporting. Customers using RecVue’s unified approach have benefited by closing their books earlier, reducing their compliance risk, and significantly lowering their total cost and overhead.
“We’ve been able to significantly reduce the cost and complexity of our revenue operations using RecVue’s OLM suite of applications,” said Philipp Lustenberger, CFO, General Assembly, part of Adecco group. “Automating, streamlining, and optimizing our order-to-cash process has helped our finance and operations teams focus more on the strategic challenges that we face.”
Mark Thomason, IDC’s Research Director for Digital Business Models and Monetization said, “The COVID-19 pandemic has accelerated the trend toward recurring business models and selling over new digital channels, including multi-partner marketplaces. This has increased monetization complexity and the need to scale quickly. Future-focused companies are adopting agile monetization systems such as RecVue’s OLM suite to easily implement complex recurring business models, automate the order-to-cash process, and easily manage partner settlement to enable the goal of continuous accounting close.”
About RecVue
RecVue empowers enterprises to modernize their billing and revenue operations at speed and scale by harnessing previously untapped revenue potential and leveraging front-office CRM data and back-office ERP systems to influence business decisions. Trusted by the world’s leading companies in business services, transportation and logistics, financial services, media and technology, including Hertz, General Assembly, ACI Worldwide, and Textainer, RecVue’s suite of purpose-built cloud applications enable enterprises to expand recurring revenue and automate complex order-to-cash (O2C) processes. For more information, visit www.recvue.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom